A Study of the effects of Lumacaftor/Ivacaftor Treatment in Subjects - Trial 2023-000946-41

Name: Clinical Trial 2023-000946-41
Creator: Vertex Pharmaceuticals Incorporated
Keywords: Cystic Fibrosis, clinical trial

Access comprehensive clinical trial information for 2023-000946-41 through Pure Global AI's free database. This phase not specified trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently status unknown. The study focuses on Cystic Fibrosis.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2023-000946-41

Trial Details

EU Clinical Trials Register • 2023-000946-41

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

A Study of the effects of Lumacaftor/Ivacaftor Treatment in Subjects

Study Focus

Disease/Condition

Cystic Fibrosis

Sponsor & Location

Primary Sponsor

Vertex Pharmaceuticals Incorporated

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

Safety and tolerability as assessed by the number of adverse events

ICD-10 Classifications

Cystic fibrosis

Cystic fibrosis, unspecified

Cystic fibrosis with other manifestations

Cystic fibrosis with pulmonary manifestations

Cystic fibrosis with intestinal manifestations

Data Source

Registry

EU Clinical Trials Register

Trial ID

2023-000946-41

Type

Non-Device Trial